

SCIENTIFIC PROGRAM 2026

Maison de la Chimie, Paris January 19-21, 2026

1 annual meeting

parislivermeeting.com





Welcome to the Paris International Liver Meeting 2026!

Dear Colleagues,

It is our great pleasure to welcome you on behalf of the Scientific Committee to the Paris International Liver Meeting, which will be held in the beautiful city of Paris from January 19-21, 2026.

This meeting will bring together leading experts, clinicians, researchers, biopharmaceutical industry and healthcare professionals from around the world to share the latest clinically relevant advances in the management and treatment of chronic liver diseases. Also, this meeting will bring together all important stakeholders to interact and share practical perspectives about important liver diseases.

Over three days, the program will explore and provide up-to-date short reviews by the best experts on the different aspects of clinical hepatology, including MASLD, MetALD, ALD, viral hepatitis, cholestatic liver diseases, HCC and complications of cirrhosis.

Over the course of the meeting, you will have the opportunity to interact with thought leaders, attend thought-provoking sessions, contribute to discussions and interact with leading biopharmaceutical leaders in liver disease that we hope will not only deepen your knowledge, but also be helpful in your clinical practice.

Paris, with its rich history and vibrant atmosphere, provides the perfect setting for this exchange of ideas, and we hope you will also enjoy the many cultural and culinary delights the city has to offer.

Join us at the prestigious Maison de la Chimie for a fruitful and productive meeting!

Laurent Castera, MD PhD

Zobair M. Younossi, MD

Co-Chairs, Paris International Liver Meeting





MONDAY, 19 JANUARY - MORNING

01:00 - 02:00 PM Workshops (4 - TBD)

08:30 - 08:50 AM	WELCOME DESK OPENING
08:50 - 09:00 AM	INTRODUCTION Laurent Castera (FR) & Zobair Younossi (US)
09:00 - 10:30 AM	SESSION 1: Hepatitis B – D Optimal Management Chairs: Pietro Lampertico (IT) & Sabela Lens (ES)
09:00-09:15 09:15-09:30	EASL/AASLD 2025 HBV guidelines Markus Cornberg (DE) HDV new insights from virology to epidemiology and natural history Maurizia Brunetto (IT)
09:30-09:45 09:45-10:00	HDV therapy: BLV monotherapy and combination Tarik Asselah (FR) HDV therapy: new antiviral therapies (phase 2 studies) Pietro Lampertico (IT)
10:00-10:30	Panel discussion (Moderator Sabela Lens)
10:30 - 11:00 AM	COFFEE BREAK
11:00 - 12:30 PM	SESSION 2: Advances in the Management of Cirrhosis Complications Chairs: Annalisa Berzigotti (CH) & Adrian Gadano (AR)
11:00-11:15	What new evidence and definitions have been further developed with Baveno VII and beyond Annalisa Berzigotti (CH)
11:15-11:30	Transjugular intrahepatic porto-systemic shunt (TIPS): Expanding Indications and Refining Risk Stratification Dominique Thabut (FR)
11:30-11:45	Acute Kidney Injury in Cirrhosis: an update from the ADQI and International Club of Ascites (ICA) Consensus Claire Francoz (FR)
11:45-12:00	New challenges in SBP prophylaxis: Beyond the guidelines Paolo Angeli (IT)
12:00-12:30	Panel Discussion (Moderator Adrian Gadano)
12:30 - 01:00 PM	LUNCH SYMPOSIUM (PRODUCT THEATER)

CET (Central European Time) or UTC +1



MONDAY, 19 JANUARY - AFTERNOON

02:00 - 02:30 PM	STATE OF THE ART LECTURE Fibrosis in MASH: A Surrogate for Mortality and Endpoint for Treatment Massimo Pinzani (IT)
02:30 - 04:00 PM	SESSION 3: Advances in the Management of HCC Chairs: Josep Llovet (ES-US) & Massimo Pinzani (IT)
02:30-02:45	Overview of Guidelines of HCC management (EASL, AASLD, ESMO) Josep M Llovet (ES-US)
02:45-03:00	Advances in the management of early/intermediate HCC Riccardo Lencioni (IT)
03:00-03:15	Advances in the management of advanced HCC Lorenza Rimassa (IT)
03:15-03:30	Emerging therapies David Pinato (UK)
03:30-04:00	Panel discussion (moderator Massimo Pinzani)
04:00 - 04:30 PM	COFFEE BREAK
04:30 - 05:30 PM	Workshops (1 hour case-based practical interactive sessions on special topics related to MASLD, MetALD, ALD, HBV/HDV, cholestatic liver disease, complications of cirrhosis and HCC)
05:30 PM	CONCLUSION DAY 1

Laurent Castera (FR) & Zobair Younossi (US)



TUESDAY, 20 JANUARY - MORNING

08:30 - 09:30 AM	WORKSHOPS
	(1 hour case-based practical interactive sessions on special topics related to
	MASLD, MetALD, ALD, HBV/HDV, cholestatic liver disease, complications of

cirrhosis and HCC)

09:30 - 11:00 AM	SESSION 4: MASLD Epidemiology, Economic Impact, and Risk
	Stratification Using NITs

Chairs: Manolis Tsochatzis (UK) & Laurent Castera (FR)

09:30-09:45	Epidemiology and financial impact of MASH Zobair Younossi (US)
09:45-10:00	NIT algorithms for identifying high risk patients with MASH
	Jérôme Boursier (FR)
10:00-10:15	Non-invasive tests for treatment response in MASH
	Manolis Tsochatzis (UK)
10:15-10:30	Pulling it all together: the use of NITs in clinical practice of MASH
	Vincent Wong (HK)
10:30-11:00	Panel discussion (moderator Laurent Castera)

11:00 - 11:30 AM COFFEE BREAK

11:30 - 12:55 PM SESSION 5: MASLD Treatment

Chairs: Mazen Noureddin (US) & Vincent Wong (HK)

11:30-11:45	Lifestyle modifications for patients with MASH Shira Zelber-Sagi (IL)
11:45-12:00	Treatment of MASH-Co Morbidities (type 2 diabetes)
	Elisabetta Bugianesi (IT)
12:00-12:15	Current treatment of MASH Mazen Noureddin (US)
12:15-12:30	Future treatments of MASH: What is in the pipeline? Frank Tacke (DE)
12:30-12:55	Panel Discussion (moderator Vincent Wong + Michael Betel
	patient representative)

01:00 - 02:00 PM LUNCH SYMPOSIUM (PRODUCT THEATER)



TUESDAY, 20 JANUARY - AFTERNOON

02:00 - 03:00 PM SYMPOSIUM

03:00 - 03:30 PM SPECIAL LECTURE

Screening for liver disease in the general population: the LiverScreen

Story Pere Gines (ES)

03:30 - 04:00 PM COFFEE BREAK

04:00 - 05:30 PM SESSION 6: MetALD and ALD

Chairs: Maja Thiele (DK) & Christophe Moreno (BE)

04:00-00:15 Update on diagnosis of MetALD Maja Thiele (DK)

04:15-04:30 The natural history of MetALD Hannes Hagström (SE)

04:30-04:45 Update on ALD Ramon Bataller (ES)

04:45-05:00 Pharmaceutical and non-pharmaceutical treatment for MetALD and ALD

Mark Thursz (UK)

05:00-05:30 **Panel discussion** (Christophe Moreno moderator)

05:30 PM CONCLUSION DAY 2

Laurent Castera (FR) & Zobair Younossi (US)



WEDNESDAY, 21 JANUARY - MORNING

08:30 - 09:45 AM SESSION 7: Current Optimal treatment and Future Innovations in PBC

and PSC

Chairs: Andreas Kremer (CH) & Ana Lleo (IT)

08:30-08:45 How to treat and assess risk in a patient with PBC? **David Jones (UK)**

08:45-09:00 How to treat and monitor a patient with PSC? Andreas Kremer (CH)

09:00-09:15 Future treatment for PBC and PSC Ana Lleo (IT)

09:15-09:45 Panel Discussion

10:00 - 11:00 AM SYMPOSIUM

11:00 - 11:30 AM COFFEE BREAK

11:30 - 12:00 AM STATE OF THE ART

Advances in hepatic encephalopathy

Debbie Shawcross (UK)

12:00 - 01:00 PM SESSION 8: R&D - The drug pipelines presented by sponsors

(10 min each)

Chairs: Laurent Castera (FR) & Zobair Younossi (US)

01:00 PM CONCLUSION DAY 3

Laurent Castera (FR) & Zobair Younossi (US)



Co-Chairs



Laurent CASTERA, MD, PhD FRANCE

Professor of Hepatology, Head of the NASH/MASH Program
Department of Hepatology, Hôpital Beaujon, AP-HP
INSERM UMR 1149, Centre de Recherche sur l'Inflammation Paris Montmartre,
Université Paris-Cité, Clichy, France



Zobair M YOUNOSSI, MD, MPH USA

Chairman of the Global NASH/MASH Council, Washington DC, USA Professor and Chairman of Beatty Liver and Obesity Research, Inova Health System, Falls Church, VA, USA





Scientific Committee



Annalisa BERZIGOTTI, MD, PhD SWITZERLAND

Full Professor of Clinical Hepatology at the University of Berne and Chief of Hepatology and Co-Director of the Department of Visceral Surgery and Medicine of the Inselspital, University Hospital of Berne



Adrian GADANO, MD, PhD ARGENTINA

Head of the Research Department at the Hospital Italiano de Buenos Aires



Andreas KREMER, MD, PhD SWITZERLAND

Head of Hepatology and Vice Director of the Department of Gastroenterology and Hepatology, University Hospital Zurich



Pietro LAMPERTICO, MD, PhD ITALY

Full Professor in the Gastroenterology, Director of the Gastroenterology and Hepatology Division, Head of the "A. M. e A. Migliavacca" Center for Liver Disease at the Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, University of Milan



Josep LLOVET, MD, PhD SPAIN

Full Professor of Medicine and Director of the Liver Cancer Program at Icahn School of Medicine at Mount Sinai (New York - USA)

ICREA Research Prof at IDIBAPS-Hospital Clínic and Full Prof of Medicine-Hepatic

Oncology at the Univ. of Barcelona



Scientific Committee



Mazen NOUREDDIN, MD, MHSc USA

Professor of Medicine at the Lynda K. and David M. Underwood Center for Digestive Disorders J.C. Walter Jr. Transplant Center Sherrie & Alan Conover Center for Liver Disease & Transplantation at Houston Methodist Hospital



Massimo PINZANI, MD, PhD ITALY

Emeritus Professor of Medicine at University College London (UCL) (UK) Scientific Director of UPMC (University of Pittsburgh Medical Center)-ISMETT IRCSS in Palermo



Maja THIELE, MD, PhD DENMARK

Professor of Hepatology at Department of Gastroenterology and Hepatology, Odense University Hospital and University of Southern Denmark



Manolis TSOCHATZIS, MD, MSc UNITED KINGDOM

Professor of Hepatology and Consultant Hepatologist at the UCL Institute for Liver and Digestive Health, Royal Free Hospital in London



Vincent WONG, MD HONG KONG

Mok Hing Yiu Professor of Medicine and head of the Division of Gastroenterology and Hepatology at The Chinese University of Hong Kong



Faculty

FACULTY

ANGELI Paolo LENS GARCÍA Sabela

ASSELAH Tarik LLEO Ana

BATALLER Ramon LLOVET Josep

BERZIGOTTI Annalisa MORENO Christophe

BETEL Michael NOUREDDIN Mazen

BOURSIER Jérome PINATO David

BRUNETTO Maurizia PINZANI Massimo

BUGIANESI Elisabettta RIMASSA Lorenza

CASTERA Laurent SHAWCROSS Debbie

CORNBERG Markus TACKE Frank

FRANCOZ Claire THABUT Dominique

GADANO Adrian THIELE Maja

GINES Pere THURSZ Markus

HAGSTRÖM Hannes TSOCHATZIS Manolis

JONES David WONG Vincent

KREMER Andreas YOUNOSSI Zobair

LAMPERTICO Pietro ZELBER SAGI Shira

LENCIONI Riccardo